This webinar will provide an update on the ongoing COVID-19 pandemic by focusing on both ends of spectrum from infection prevention to management of severe disease. Speakers will summarize relevant clinical trial data from COVID-19 vaccination trials and what it means for our patients; and also discuss basic pathophysiology of COVID-19 related acute respiratory distress syndrome and new insights in management via extra corporeal membrane oxygenation (ECMO).
 

Moderators: Robin Vos, MD, PhD and Stephanie Pouch, MD, MS

COVID-19 Vaccination
Emily Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA
Summarize current clinical trial data, including effect on viral variants as well as impact on transplant recipients.

ECMO for COVID-19-related ARDS: Evidence and Patient Selection
Daniel Brodie, MD, Columbia University Department of Medicine, New York, USA
This talk will explore the emerging evidence for the use of ECMO in patients with COVID-19-related ARDS and how this evidence informs patient selection.

ECMO as bridge to lung transplantation in COVID-ARDS: to whom and when?
Marcelo Cypel, MD, University Health Network, Toronto, Canada
This talk will explore when to consider a COVID-ARDS patients on mechanical support for lung transplant assessment and to balance the decisions between the possibility of patient recovery with or without a transplantation

Live Q&A Segment with All Speakers

ISHLT Announcements
Greg Schultz, CEO, ISHLT, Addison, TX, USA
 

Continuing Education Information

Learning Objectives – at the conclusion of this session, attendees will be able to discuss:

• Current clinical trial data, including effect on viral variants as well as impact on transplant recipients
• The emerging evidence for the use of ECMO in patients with COVID-19 related ARDS and how this evidence informs patient selection.
• When to consider a COVID-ARDS patients on mechanical support for lung transplant assessment and to balance the decisions between the possibility of patient recovery with or without a transplantation.
   

Target Audience – The target audience for the March 2021 webinar session includes physicians, surgeons, scientists, pharmacists, nurses, transplant coordinators and other allied health and social science professionals engaged in the management and treatment of patients with advanced heart or lung disease, basic science or clinical research related to these fields, or other specialties which cause them to become involved in the treatment of patients with advanced heart or lung disease.

Activity Designed to Change – This activity is designed to change knowledge and competence.

Learning Attributes   Patient Care and Medical Knowledge

Disclosures – Current guidelines state that participants in continuing medical and allied health professional education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation or service as Chair/Planner. Disclosures will be distributed in the Learner Notification that you receive as a participant prior to the live virtual session. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

Disclaimer – The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the ISHLT.

Documenting CME Credits – The ISHLT provides CME certificates to those who have participated in an ISHLT educational activity. The ISHLT does not submit credits to regulating bodies or certifying organizations on behalf of the participants. It is the participants responsibility to submit proof of credits on his or her own behalf.